Rheumatic diseases and pregnancy by Gcelu, A
CONTINUING MEDICAL EDUCATION
    September 2014, Vol. 104, No. 9
Systemic lupus 
erythematosus 
Rheumatic diseases predominantly affect young women 
of childbearing age; therefore pregnancy is a topic of 
major interest. Pregnancy-induced changes in immune 
function can have an effect on underlying disease activity.[1-3] Pregnant 
women with rheumatic diseases constitute a high-risk population, with 
potential adverse fetal and maternal outcomes. Treatment options can be 
limited in pregnant women owing to concerns about the adverse effects 
of commonly used medication on the fetus.[4]
Systemic lupus erythematosus (SLE) is a multisystem disease and 
the most prevalent autoimmune disease affecting women during 
their reproductive years, with an incidence of 1/1  000 women.[5] 
Women with SLE have normal fertility but may have complicated 
pregnancies.[6] Prior exposure to cyclophosphamide is the main risk 
factor for infertility,[5,6] and is related to dosing and age of the patient, 
with exposure for patients older than 35 years carrying a higher risk 
of premature ovarian failure.[6]
Effects of pregnancy on systemic lupus erythematosus 
The concern during pregnancy is the increased incidence of lupus 
flares. Measurable disease activity is thought to be present in 40 - 50% 
of pregnancies, with the most common manifestations being lupus 
nephritis, cutaneous disease, arthritis, and haematological disease, 
especially thrombocytopenia.[2] About 75% of patients who flare during 
pregnancy will have lupus nephritis.[2] Lupus flares occur throughout 
pregnancy but the rate seems higher during the third trimester and 3 
months postpartum.[6] Increased SLE disease activity is expected during 
pregnancy or in the postpartum period because of increased levels of 
oestrogen, prolactin and Th2 cytokines.[2,7] Several studies have shown 
that the risk of flare during pregnancy is increased in women who 
have active disease in the 6 - 12 months before conception, in those 
who discontinue useful medications, in particular hydroxychloroquine, 
and in those with active lupus nephritis at conception or during the 
previous 6 months.[2,8] The latter is associated with an increased risk 
of progression to end-stage renal disease.[2] All SLE patients should be 
counselled and evaluated before pregnancy. Women with active disease, 
who are not actively planning a pregnancy, or are taking drugs that are 
contraindicated during pregnancy, need reliable contraception. 
Effects of systemic lupus erythematosus on pregnancy 
outcome
SLE patients have a 2 - 4-fold higher rate of pregnancy complications 
than an equivalent population without SLE.[9] Pre-eclampsia occurs 
in about 23% of women with the disease, especially in those with 
co-existing antiphospholipid syndrome. This is approximately three 
times higher than the 7% occurrence rate in a population without the 
disease.[9] Fetal loss (miscarriage or stillbirth) occurs in about 20% of 
pregnancies in women with SLE.[6,8] While the risk of miscarriage is 
not significantly elevated, the risk of stillbirth is significantly higher 
compared with that in the general population.[2] The increased risk 
of stillbirth is related to increased lupus activity and the presence of 
antiphospholipid antibodies.[2,8] Patients with active lupus nephritis 
in the 6 months prior to conception or during pregnancy are at 
higher risk for pregnancy-related complications than SLE patients 
without renal disease, including spontaneous abortion, premature 
abortion, premature delivery, intrauterine growth restriction and pre-
eclampsia.[2] SLE patients with higher disease activity in combination 
with low complement levels or a positive anti-double-stranded DNA 
(dsDNA) have the highest rate of pregnancy loss and preterm birth.[2] 
The most common fetal morbidity in SLE patients is prematurity and 
intrauterine growth retardation (IUGR), with preterm deliveries ranging 
between 17% and 49%.[2] Lupus flare and pre-existing hypertension 
are the strongest predictors.
One of the major challenges is assessing a disease flare in 
pregnancy, as some of the physiological changes that may occur in 
pregnancy and pregnancy-related complications might mimic a lupus 
flare. Table 1 shows features that may help to diagnose a lupus flare.[6]
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Antiphospholipid syndrome 
Antiphospholipid syndrome (APS) is a systemic autoimmune disorder 
defined by the occurrence of recurrent vascular (venous and arterial) 
thrombosis and pregnancy morbidity in the presence of persistently 
elevated antiphospholipid antibodies (aPL), anticardiolipin IgG/
IgM, lupus anticoagulant and anti-β2-glycoprotein-1 IgG/IgM.[1] APS 
affects women more commonly than men and is typically diagnosed 
between the ages of 30 and 40 years. APS can present alone (primary 
APS) or in the context of an underlying connective tissue disease 
(secondary APS). Patients with SLE will test positive for aPL in up 
to 65% of cases, but only about half of these will develop thrombosis 
and/or pregnancy morbidity (APS).[1] One study revealed that APS 
was associated with SLE in 36% of cases.[1] 
Pregnancy and the first 6 weeks postpartum are known to 
be associated with a prothrombotic state with increased risk of 
developing deep vein thrombosis, pulmonary embolism and stroke.[6] 
Venous thromboembolism is 2 - 4-fold more common in pregnancy 
after caesarean section than after vaginal delivery. Thrombotic 
complications are found in 1.7% of SLE pregnancies.[9] Pregnancy in 
patients with APS represents an additional thrombotic risk.
Effects of antiphospholipid syndrome on pregnancy 
outcome
APS is one of the most important acquired causes of pregnancy loss.[8] 
Women with aPL had an increased incidence of pregnancy loss after 10 
weeks of gestation compared with an unselected obstetric population 
with 10 - 15% of pregnancy losses, which occurred mainly during 
the pre-embryonic (<6 weeks’ gestation) or embryonic (6 - 9 
weeks’ gestation) period.[1,8] The prevalence of aPL in the general 
obstetric patient is <2%; therefore universal screening cannot be 
justified.[1] Women with a history of three or more first trimester 
pregnancy losses should be screened for aPL. All the above aPL 
should be measured to determine whether someone is aPL-negative. 
It is recommended that women with APS-related thrombosis be 
given prophylaxis during pregnancy, a combination of heparin 
(unfractionated or low molecular weight) and low-dose aspirin.[10] 
Several studies have reported pre-eclampsia in 20 - 50% of patients with 
APS, which usually manifests early and is severe.[8] Beta-2 glycoprotein-1 
has a predictive value for the occurrence of pre-eclampsia.[1]  The HELLP 
(haemolysis, elevated liver enzymes, and low platelets) syndrome has 
been reported in APS pregnancies and usually occurs earlier than in 
the general obstetric population (second trimester).[11] Uteroplacental 
insufficiency has been noted to induce IUGR in 30% of APS patients, 
preterm delivery in 30%, and pre-eclampsia.[1]
Sjögren’s syndrome
Sjögren’s syndrome is a chronic autoimmune inflammatory disease 
affecting primarily the exocrine glands, but also the extra-glandular 
structures. It can present alone (primary Sjögren’s syndrome (pSS)) or 
be part of an underlying connective tissue disease, most commonly 
rheumatoid arthritis (RA) or SLE, and is then regarded as secondary 
Sjögren’s syndrome.[12]
pSS is 10 times more frequent in women than in men, with a peak 
incidence at or near menopause.[1] Disease onset in pSS is when most 
patients have completed their families and therefore there is a paucity 
of data on pregnancy outcomes in this disease. Pregnancy, however, 
does not appear to have any effect on pSS as there are no major 
changes in symptoms. 
Effects of primary Sjögren’s syndrome on pregnancy 
outcome
Previous studies observed an increased rate in spontaneous abortions 
in women with pSS, but advanced maternal age of the first pregnancy 
could explain the increased impact of pregnancy complications.[12] 
Results of a recent study indicate that women with pSS experience 
complicated pregnancies more frequently than controls, with an 
increased rate of preterm delivery, caesarean section and low-
birth-weight infants.[12] Patients with pSS are known to have a high 
prevalence of Ro/SSA and La/SSB antibodies but these can be present 
in other connective tissue diseases, particularly in SLE. Maternal 
transmission of IgG antibodies to the fetus usually occurs between 
weeks 16 and 32.[6] Transmission of maternal Ro and La antibodies 
during pregnancy can cause neonatal lupus syndrome (NLS) in 
neonates, manifesting as transient cutaneous lupus lesions, cytopenia, 
hepatic and other systemic manifestations or complete heart block 
(CHB).[1] CHB is the only permanent manifestation of NLS,[1] with 
an estimated incidence of 1 - 2% and a 15 - 20% recurrence rate 
if the first child had CHB.[1,2,7,8] Unfortunately there is no effective 
prophylactic therapy to prevent recurrence of CHB. The other clinical 
manifestations resolve within 4 - 6 months after birth.[2] NLS can lead 
to death in 15 - 30% of cases owing to cardiac manifestations.[7] About 
67% of surviving affected children require permanent pacing before 
adulthood, the majority by the age of 1 year, and a third will need 
insertion of a pacemaker within the first 3 months of life.[7]
Mothers with Ro and La antibodies should have their fetal heart rate 
assessed weekly and have serial echocardiograms from 16 weeks until 
about 25 weeks of gestation, and less frequently thereafter.[7,8] The aim 
is to detect early fetal abnormalities that might precede CHB and offer 
intrauterine therapy to improve atrioventricular conduction speed.[12] 
Maternal treatment with fluorinated steroids, e.g. dexamethasone, 
can reduce the antibody-mediated inflammatory damage of nodal 
tissue, but these drugs should not be used prophylactically in the 
absence of symptoms.[8] Recent data suggest that hydroxychloroquine 
during pregnancy may reduce the incidence of congenital CHB in 
women with anti-Ro and anti-La antibodies.[13]
Systemic sclerosis 
Systemic sclerosis (SSc) is an autoimmune connective tissue disease 
characterised by fibrosis of the skin and internal organs, and 
pronounced alterations in the microvasculature. It predominantly 
affects women, with a peak age of onset around 40 - 50 years,[1] 
leaving the potential to become pregnant after the onset of disease. 
It seems that pregnancy does not profoundly alter the disease. There 
may be aggravation of symptoms, in particular gastro-oesophageal 
reflux disease.[6] Raynaud’s phenomenon improves and cutaneous 
disease remains stable during pregnancy and postpartum.[14] 
Table 1. Features helpful for diagnosis of lupus flares in 
pregnancy
Unreliable features Reliable features
Facial/palmar erythema Palpable lupus rash
Alopecia Synovitis
Arthralgia Mucosal ulcers
Anaemia Leucopenia (lymphopenia)
Thrombocytopenia Red cells and/or casts in urine
Seizures Rising anti-dsDNA
Hypertension Reduced C3 and C4 (≥25%)
Proteinuria
Low C4
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Serious organ manifestations of SSc can threaten the outcome 
of pregnancy.[1,14] The greatest risk in pregnancy to mother and 
fetus comes from a renal crisis, which can manifest as acute-onset 
hypertension or progressive renal failure and occur at any stage 
of pregnancy.[6,14] Renal crisis can be difficult to distinguish from 
pre-eclampsia.[6] Hypertensive disorders including pre-eclampsia 
have been found to be higher in SSc pregnancies, but the frequency 
of occurrence of renal crisis in pregnancy compared with non-
pregnant SSc patients is similar.[1] Risk factors for renal crisis are early 
diffuse SSc, rapidly progressing skin disease and high-dose steroids. 
Although angiotensin converting enzyme (ACE) inhibitors are not 
normally advised in pregnancy as they are associated with congenital 
abnormalities, they are essential to control hypertension and the 
associated renal crisis in pregnant patients with SSc.[6,14] Another 
major risk factor is pulmonary hypertension (PHT). PHT poses a 
30 - 50% maternal mortality risk in pregnancy[15] and therefore a 
multidisciplinary team approach is required to manage these high-
risk patients for a better pregnancy outcome. Preterm deliveries, 
IUGR and very-low-birth-weight infants are significantly more 
frequent in SSc than in healthy women, but the risk of miscarriage 
is the same.[1]
Rheumatoid arthritis 
RA is an autoimmune disease that results in a chronic, systemic 
inflammatory disorder that may affect many tissues, but principally 
affects synovial joints and can lead to significant joint destruction 
and disability. Women are two to three times more likely to develop 
RA than men, with an incidence of 1/2 000 during the childbearing 
years.[5] In contrast to SLE, RA patients experience significant 
improvement in disease activity during pregnancy, with up to 75% of 
pregnant women experiencing improvement in their RA symptoms 
and over 50% improving during the first trimester.[1,2] A small 
proportion of patients achieve complete remission. The trend is 
that disease activity continues to improve as gestation progresses 
and becomes most improved in the third trimester.[16] Patients with 
high disease activity benefit the most. A recent study has shown that 
women who were negative for both rheumatoid factor and anticyclic 
citrullinated peptide – diagnostic antibody tests in RA – were more 
likely to improve in RA symptoms than those who were antibody-
positive (75% v. 39%).[17]
However, the majority of patients have recurrent disease, 
particularly in the initial 3 - 12 months postpartum, with up to 
62% requiring increased drug therapy within the first 6 months 
postpartum.[16]
The improvement in RA symptoms during pregnancy is thought 
to be due to the immunological changes associated with pregnancy, 
resulting in an increase in T helper 2 (Th2) cytokines, particularly 
interleukin 10 (IL-10), and the effects of hormonal changes.[2,6,18] In 
addition, pregnancy promotes the development of regulatory T cells 
that suppress maternal autoimmune responses associated with the 
disease.[2,6,18] 
The increased risk of developing RA postpartum is thought to be 
related to the effects of prolactin, the levels of which are increased 
during lactation.[2,6] Studies, however, have failed to demonstrate a 
correlation between a disease flare and breastfeeding.[1]
It was previously thought that there was no risk to pregnancy 
outcome in women with RA, but a recent study found that there is a 
higher rate of lower mean birth weight and elective caesarean section 
than in healthy women.[1] Another study showed that lower birth 
weight is independently correlated with disease activity.[1]
Psoriatic arthritis 
Psoriatic arthritis (PsA) is an inflammatory arthritis associated with 
psoriasis and has an equal gender distribution. Disease activity in PsA 
behaves in the same manner as in RA in articular disease, with up to 
85% of patients improving during pregnancy.[1] Pregnancy, however, 
does not have any effect on skin disease.[1] Postpartum relapse occurs 
in 60 - 80% of patients 2 - 12 weeks postpartum. There is no evidence 
to support increased adverse pregnancy outcomes in women with 
PsA.
Ankylosing spondylitis 
Ankylosing spondylitis (AS) is a chronic, systemic inflammatory 
disease affecting the axial skeleton, the entheses (sites of bony 
insertions of tendons and ligaments) and, occasionally, the peripheral 
joints. The hallmark of AS is inflammatory backache, and the disease 
predominantly affects men. There seems to be no improvement in 
symptoms during pregnancy in patients with AS.[3] Previous studies 
show that disease activity remains high until early in the second 
trimester,[3] with up to 70% of patients needing NSAIDs.[1] Disease 
activity decreases in the third trimester, but complete remission is 
not achieved as in RA. Postpartum relapse occurs in 50 - 80% of AS 
patients within 4 - 12 weeks after delivery.[1]
The rate of adverse pregnancy outcomes is the same as for healthy 
women; however, caesarean section is frequently performed in patients 
with AS. Ankylosis of the sacro-iliac joints, hip disease or total hip 
replacement does not preclude normal delivery.[1]
Drug treatment during pregnancy
Adjustment of drug therapy in patients who are planning to become 
pregnant and those who are already pregnant is necessary to ensure 
that the underlying maternal disease is quiescent and that the drugs 
used are safe and compatible with embryonic and fetal development.[19] 
Withdrawal of all drugs used prior to conception may result in a disease 
flare-up, which may be as catastrophic for pregnancy outcome as 
continuing with drugs that are harmful to the developing fetus.
Table 2 summarises the list of drugs that are safe and those that are 
contraindicated during pregnancy to treat rheumatic diseases.   
Management of patients with anti-
rheumatic diseases
Pregnancy in a woman with rheumatic diseases can have an increased 
risk of adverse maternal and fetal outcomes. Risks in the mother 
depend on disease activity before conception and throughout 
pregnancy, extent of organ involvement and presence of certain 
types of auto-antibodies.[19] Risks for the fetus are related to maternal 
disease activity, presence of auto-antibodies and maternal therapy.[19]
Women with rheumatic diseases who intend becoming pregnant 
should be provided with a preconception medical work-up that 
includes a complete clinical and laboratory assessment precisely 
reviewing risk factors and assessing the status of disease: anti-Ro and 
La, aPL, anti-dsDNA, complement level C3 and C4, kidney function, 
urinary protein, full blood count and inflammatory markers. The 
objective is to plan pregnancy during remission and withdraw 
medications that are not safe during pregnancy. An interdisciplinary 
team should manage high-risk patients. 
All SLE patients should be on hydroxychloroquine, as it has 
been shown to prevent lupus flare-ups, have moderate protection 
against thrombosis and reduce development of CHB in children of 
mothers positive for Ro and La antibodies. Hydroxychloroquine 
should be continued in SLE patients and in those positive for Ro and 
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La antibodies throughout pregnancy. APS patients should receive 
prophylaxis with low-dose aspirin in combination with heparin. ACE 
inhibitors are essential to control hypertensive renal crisis in systemic 
sclerosis, even in pregnancy. Patients with inflammatory arthritis 
who improve during pregnancy should be counselled for postpartum 
relapse and therapy planned accordingly. 
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Table 2. Drug treatment during pregnancy[1,4,6,19]
Drug Contraindicated Recommendations
Paracetamol No Safe throughout pregnancy
Codeine No Use with caution: respiratory distress and withdrawal syndrome
Non-steroidal anti-inflammatory drugs No Safe until 32 weeks’ gestation: closure of ductus arteriosus
Aspirin No Use low dose
Steroids No Keep at ≤15 mg in 1st trimester
Chloroquine No Safe throughout pregnancy
Azathioprine No Safe throughout pregnancy
Cyclosporine No Safe throughout pregnancy
Salazopyrine No Safe throughout pregnancy
Tacrolimus No Safe throughout pregnancy
Methotrexate Yes Discontinue 3 months before conception
Leflunomide Yes Stop and wash out before pregnancy
Cyclophosphamide Yes Discontinue 3 months before conception, and pregnancy test before next infusion
Mycophenolate mofetil Yes Discontinue 6 weeks before conception
Abatacept Yes Discontinue 3 months before conception
Rituximab Yes Discontinue 6 - 12 months before conception
Tocilizimab Yes Discontinue 3 months before conception
Etanercept Yes Discontinue at missed period or after a positive pregnancy test
Certolizumab No Can be given throughout pregnancy: minimal passage to fetus
Monoclonal antibodies (adalimumab, 
infliximab, golimumab)
Yes Discontinue at missed period or after a positive pregnancy test
